Ativan Injection contains the active ingredient lorazepam at a concentration of 4 mg/ml.
Lorazepam (INN, BAN) is chemically defined as 7-chloro-5-(o-chlorphenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one.
Solution for injection
Clear, colourless solution supplied in clear glass ampoules containing 4 mg lorazepam in 1 ml of solution.
Pre-operative medication or premedication for uncomfortable or prolonged investigations e.g. bronchoscopy, arteriography, endoscopy.
The treatment of acute anxiety states, acute excitement or acute mania.
The control of status epilepticus.
Dosage and duration of therapy should be individualised. The lowest effective dose should be prescribed for the shortest time possible.
Treatment in all patients should be withdrawn gradually to minimise possible withdrawal symptoms (See Special Warnings and Precautions for Use).
Ativan Injection can be given intravenously or intramuscularly. However, the intravenous route is to be preferred. Care should be taken to avoid injection into small veins and intra-arterial injection.
Absorption from the injection site is considerably slower if the intramuscular route is used and as rapid an effect may be obtained by oral administration of lorazepam.
Ativan should not be used for long-term chronic treatment.
Preparation of the injection
Ativan Injection is slightly viscid when cool.
A 1:1 dilution of Ativan Injection with normal saline or Sterile Water for Injection BP is recommended in order to facilitate intramuscular administration.
For intravenous administration, Ativan Injection should always be diluted with saline or Sterile Water for Injection BP as a 1:1 dilution.
Ativan Injection is presented as a 1ml solution in a 2ml ampoule to facilitate dilution.
Ativan Injection should not be mixed with other drugs in the same syringe.
Adults: 0.05mg/kg (3.5mg for an average 70kg man). By the intravenous route the
injection should be given 30-45 minutes before surgery when sedation will be evident after 5-10 minutes and maximal loss of recall will occur after 30-45 minutes.
By the intramuscular route the injection should be given 1-11/2 hours before surgery when sedation will be evident after 30-45 minutes and maximal loss of recall will occur after 60-90 minutes.
Children: Ativan Injection is not recommended in children under 12.
2. Acute Anxiety
Adults: 0.025-0.03mg/kg (1.75-2.1mg for an average 70kg man). Repeat 6 hourly.
Children: Ativan Injection is not recommended in children under 12.
3. Status epilepticus
Elderly: The elderly may respond to lower doses and half the normal adult dose may
Patients with Renal or Hepatic impairment:
Lower doses may be sufficient in these patients (See Special Warnings and Precautions for Use). Use in patients with severe hepatic insufficiency is contraindicated.
• Acute pulmonary insufficiency.
• Hypersensitivity to benzodiazepines, including Ativan Injection or any of the vehicle constituents (polyethylene glycol, propylene glycol, benzyl alcohol).
• Sleep apnoea syndrome
• Myasthenis gravis
• Severe hepatic insufficiency
• Ativan Injection contains benzyl alcohol and is contraindicated in infants or young children, up to 3 years old.
Ativan Injection is not recommended for out-patient use unless the patient is accompanied.
Prior to use, Ativan Injection may be diluted for IM administration and should always be diluted for IV administration with equal amounts of compatible diluent (see Posology and Method of Administration). Intravenous injection should be administered slowly except in the control of status epilepticus where rapid injection is required.
The possibility that respiratory arrest may occur or that the patient may have partial airway obstruction should be considered. Therefore, equipment necessary to maintain a patent airway and to support respiration/ventilation should be available and used where necessary.
The use of benzodiazepines, including lorazepam, may lead to physical and psychological dependence.
Severe anaphylactic/anaphylactoid reactions have been reported with the use of benzodiazepines. Cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of benzodiazepines. Some patients taking benzodiazepines have had additional symptoms such as dyspnoea, throat closing, or nausea and vomiting. Some patients have required medical therapy in the emergency department. If angioedema involves the tongue, glottis or larynx, airway
obstruction may occur and be fatal. Patients who develop angioedema after treatment with a benzodiazepine should not be rechallenged with the drug.
It is recommended that patients receiving Ativan Injection should remain under observation for at least eight hours and preferably overnight. When Ativan Injection is used for short procedures on an outpatient basis, the patient should be accompanied when discharged.
Patients should be advised that their tolerance for alcohol and other CNS depressants will be diminished in the presence of Ativan Injection. Alcoholic beverages should not be consumed for at least 24 to 48 hours after receiving Ativan Injection.
Use of benzodiazepines, including lorazepam, may lead to potentially fatal respiratory depression. Extreme care must be taken in administering Ativan Injection to elderly or very ill patients and to those with limited pulmonary reserve or compromised respiratory function (eg, chronic obstructive pulmonary disease [COPD]), because of the possibility that apnoea and/or cardiac arrest may occur. Care should also be exercised when administering Ativan Injection to a patient with status epilepticus, especially when the patient has received other central nervous system depressants.
There is no evidence to support the use of Ativan Injection in coma or shock.
Ativan is not intended for the primary treatment of psychotic illness or depressive disorders, and should not be used alone to treat depressed patients. The use of benzodiazepines may have a disinhibiting effect and may release suicidal tendencies in depressed patients.
Pre-existing depression may emerge during benzodiazepine use.
There are no clinical data available for Ativan Injection with regard to abuse or dependence. However, based upon experience with oral benzodiazepines, doctors should be aware that repeated doses of Ativan Injection over a prolonged period of time may lead to physical and psychological dependence. The risk of dependence on Ativan is low when used at the recommended dose and duration, but increases with higher doses and longer term use. The risk of dependence is further increased in patients with a history of alcoholism or drug abuse, or in patients with significant personality disorders. Therefore, use in individuals with a history of alcoholism or drug abuse should be avoided.
Dependence may lead to withdrawal symptoms, especially if treatment is discontinued abruptly. Therefore, the drug should always be discontinued gradually - using the oral preparation if necessary.
Symptoms reported following discontinuation of oral benzodiazepines include headaches, muscle pain, anxiety, tension, depression, insomnia, restlessness, confusion, irritability, sweating, and the occurrence of "rebound" phenomena whereby the symptoms that led to treatment with benzodiazepines recur in an enhanced form. These symptoms may be difficult to distinguish from the original symptoms for which the drug was prescribed.
In severe cases the following symptoms may occur: derealisation; depersonalisation; hyperacusis; tinnitus; numbness and tingling of the extremities; hypersensitivity to light, noise, and physical contact; involuntary movements; vomiting; hallucinations; convulsions. Convulsions may be more common in patients with pre-existing seizure disorders or who are taking other drugs that lower the convulsive threshold, such as antidepressants.
It may be useful to inform the patient that treatment will be of limited duration and that it will be discontinued gradually. The patient should also be made aware of the possibility of "rebound" phenomena to minimise anxiety should they occur.
Withdrawal symptoms (eg, rebound insomnia) can appear following cessation of recommended doses after as little as one week of therapy.
There are indications that, in the case of benzodiazepines with a short duration of action, withdrawal phenomena can become manifest within the dosage interval, especially when the dosage is high.
When benzodiazepines with a long duration of action are being used, it is important to warn against changing to a benzodiazepine with a short duration of action, as withdrawal symptoms may develop.
Abuse of benzodiazepines has been reported.
Anxiety or insomnia may be a symptom of several other disorders. The possibility should be considered that the complaint may be related to an underlying physical or psychiatric disorder for which there is more specific treatment.
Caution should be used in the treatment of patients with acute narrow-angle glaucoma.
As with all benzodiazepines, the use of lorazepam may worsen hepatic encephalopathy.
Patients with impaired renal or hepatic function should be monitored frequently and have their dosage adjusted carefully according to patient response. Lower doses may be sufficient in these patients. The same precautions apply to elderly or debilitated patients and patients with chronic respiratory insufficiency.
As with all CNS-depressants, the use of benzodiazepines may precipitate encephalopathy in patients with severe hepatic insufficiency. Therefore, use in these patients is contraindicated.
Some patients taking benzodiazepines have developed a blood dyscrasia, and some have had elevations in liver enzymes. Periodic haematologic and liver-function assessments are recommended where repeated courses of treatment are considered clinically necessary.
Transient anterograde amnesia or memory impairment has been reported in association with the use of benzodiazepines. This effect may be advantageous when Ativan is used as a premedicant.
Paradoxical reactions have been occasionally reported during benzodiazepine use (see Undesirable effects). Such reactions may be more likely to occur in children and the elderly. Should these occur, use of the drug should be discontinued.
Although hypotension has occurred only rarely, benzodiazepines should be administered with caution to patients in whom a drop in blood pressure might lead to cardiovascular or cerebrovascular complications. This is particularly important in elderly patients.
Ativan Injection contains the excipients polyethylene glycol and propylene glycol. There have been reports of propylene glycol toxicity (e.g. lactic acidosis, hyperosmolality, hypotension) and polyethylene glycol toxicity (e.g. acute tubular necrosis) during administration of Ativan Injection, including at higher than recommended doses. Central nervous system toxicity, including seizures, as well as unresponsiveness, tachypnoea, tachycardia and diaphoresis have also been associated with propylene glycol toxicity. Those prone to propylene glycol accumulation and its potential adverse effects include patients with impaired alcohol and aldehyde dehydrogenase enzyme systems, those with renal or hepatic disease; and paediatric patients.
The sedative effects may be enhanced when the product is used in combination with alcohol. This affects the ability to drive or use machines.
The benzodiazepines, including Ativan Injection, produce additive CNS depressant effects when co-administered with other medications which themselves produce CNS depression, e.g. barbiturates, antipsychotics, sedatives/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants and anaesthetics.
Concurrent administration of lorazepam with sodium valproate may result in reduced clearance (20 to 40%) and increased concentrations of lorazepam. Therefore clinical monitoring is advised and lorazepam dosage should be reduced when appropriate.
Concurrent administration of lorazepam with probenecid may result in reduced clearance, increased elimination half-life and increased concentrations of lorazepam. Therefore clinical monitoring is advised and lorazepam dosage should be reduced when appropriate.
An enhancement of the euphoria induced by narcotic analgesics may occur with benzodiazepine use, leading to an increase in psychic dependence.
Compounds which inhibit certain hepatic enzymes (particularly cytochrome P450) may enhance the activity of benzodiazepines. To a lesser degree this also applies to benzodiazepines which are metabolised only by conjugation.
The addition of scopolamine to Ativan Injection is not recommended, since their combination has been observed to cause an increased incidence of sedation, hallucination and irrational behaviour.
Concomitant use of clozapine and lorazepam may produce marked sedation, excessive salivation, and ataxia.
Administration of theophylline or aminophylline may reduce the sedative effects of benzodiazepines, including lorazepam.
There have been reports of apnoea, coma, bradycardia, heart arrest and death with the concomitant use of lorazepam injection solution and haloperidol.
Ativan Injection should not be used during pregnancy, especially during the first and last trimesters, unless in the judgement of the physician such administration is clinically justifiable. Benzodiazepines may cause foetal damage when administered to pregnant women.
If the drug is prescribed to a woman of childbearing potential, she should be warned to contact her physician about stopping the drug if she intends to become, or suspects that she is, pregnant.
Use of Ativan Injection during the late phase of pregnancy may require ventilation of the infant at birth.
If, for compelling medical reasons, the product is administered during the late phase of pregnancy, or during labour at high doses, effects on the neonate, such as hypothermia, hypotonia and moderate respiratory depression, can be expected, due to the pharmacological action of the compound.
Infants of mothers who ingested benzodiazepines for several weeks or more preceding delivery have been reported to have withdrawal symptoms during the postnatal period.
Symptoms such as hypotonia, hypothermia, respiratory depression, apnoea, feeding problems, and impaired metabolic response to cold stress have been reported in neonates born of mothers who have received benzodiazepines during the late phase of pregnancy or at delivery.
There are insufficient data regarding obstetrical safety of parenteral Ativan, including use in cesarean section. Such use, therefore, is not recommended.
Since benzodiazepines are found in breast milk, Ativan Injection should not be given to breast feeding mothers unless the expected benefit to the woman outweighs the potential risk to the infant.
This medicine can impair cognitive function and can affect a patient’s ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive
• Do not drive until you know how the medicine affects you
• It is an offence to drive while under the influence of this medicine
• However, you would not be committing an offence (called ‘statutory defence’) if:
- The medicine has been prescribed to treat a medical or dental problem and
- You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and
- It was not affecting your ability to drive safely
Sedation, amnesia, impaired concentration and impaired muscular function may adversely affect the ability to drive or use machines. Therefore, patients should not drive or operate machinery within 24-48 hours of administration of Ativan Injection and should be advised not to take alcohol (see also Interactions).
Adverse reactions are listed in the table in CIOMS frequency categories:
Very common: Common: Uncommon: Rare:
Very rare: Undetermined:
> 1% and < 10%
> 0.1% and < 1%
> 0.01% and < 0.1%
Insufficient data to calculate significant frequencies.
System Organ Class and Frequency
Blood and lymphatic system disorders
Thrombocytopenia, agranulocytosis, pancytopenia.
Immune system disorders
Hypersensitivity reactions, anaphylactic/oid reactions, angioedema.
Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADh)
Metabolism and nutrition disorders
Confusion, depression, unmasking of depression.
Disinhibition, euphoria, suicidal ideation/attempt. Paradoxical reactions, including anxiety, agitation, excitation, hostility, aggression, rage, sleep disturbances/insomnia, sexual arousal, and hallucinations.
Nervous system disorders*
Extrapyramidal symptoms, tremor, vertigo, visual disturbances (including diplopia and blurred vision), dysarthria/slurred speech, headache, convulsions/seizures, amnesia, coma.
* Benzodiazepine effects on t CNS depression occurring wii
ie CNS are dose dependent, with more severe th higher doses.
System Organ Class and Frequency
Respiratory, thoracic and mediastinal disorders1
Respiratory depression, apnoea, worsening of sleep
Worsening of obstructive pulmonary disease.
t t wit
ie extent of respiratory depression with benzodiazepines is dose dependent h more severe depression occurring with high doses.
Increase in bilirubin, increase in liver transaminases, increase in alkaline phosphatase.
Skin and subcutaneous tissue disorders
Allergic skin reactions, alopecia.
Reproductive system and breast disorders
Change in libido, impotence, decreased orgasm.
General disorders and administration site conditions
Muscle weakness, asthenia.
Tolerance at the injection site is generally good although, rarely, pain and redness have been reported after Ativan Injection.
Transient anterograde amnesia or memory impairment may occur using therapeutic doses, the risk increasing at higher doses (see Special warnings and precautions for use).
Paradoxical reactions may be more likely to occur in children and the elderly
(see Special warnings and precautions for use).
In the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken.
Overdosage of benzodiazepines is usually manifested by degrees of central nervous system depression ranging from drowsiness to coma. In mild cases, symptoms include drowsiness, mental confusion and lethargy. In more serious cases, and especially when other CNS-depressant drugs or alcohol are ingested, symptoms may include ataxia, hypotension, hypotonia, respiratory depression, cardiovascular depression, coma and, very rarely, death.
Propylene glycol toxicity and polyethylene glycol toxicity have been reported following higher than recommended doses of Ativan Injection (See Section 4.4 Special warnings and precautions for use).
Treatment of overdosage is mainly supportive including monitoring of vital signs and close observation of the patient. An adequate airway should be maintained and assisted respiration used as needed. Hypotension, though unlikely, may be controlled with noradrenaline. Lorazepam is poorly dialysable.
The benzodiazepine antagonist, flumazenil, may be useful in hospitalised patients for the management of benzodiazepine overdosage. Flumazenil product information should be consulted prior to use. The physician should be aware of a risk of seizure in association with flumazenil treatment, particularly in long-term benzodiazepine users and in tricyclic antidepressant overdose.
Ativan is a benzodiazepine with anxiolytic, sedative, hypnotic, anticonvulsant and muscle relaxant properties.
Ativan Injection is readily absorbed when given intramuscularly. Peak plasma concentrations occur approximately 60-90 minutes following intramuscular administration.
Ativan is metabolised by a simple one-step process to a pharmacologically inactive glucuronide. There is minimal risk of accumulation after repeated doses, giving a wide margin of safety.
There are no major active metabolites. The elimination half-life is about 12-16 hours when given intramuscularly or intravenously.
Nothing of relevance to the prescriber.
Polyethylene glycol 400 Benzyl alcohol Propylene glycol
Store and transport refrigerated (2°C to 8°C).
Keep ampoule in the outer carton.
1ml solution in 2ml ampoules (Type I glass) with a one-point-cut opening, position marked by red spot in pack sizes of 10.
MARKETING AUTHORISATION HOLDER
Pfizer Limited Ramsgate Road Sandwich Kent
CT13 9NJ United Kingdom
MARKETING AUTHORISATION NUMBER(S)
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
DATE OF REVISION OF THE TEXT